United Arab Emirates to India Pharmaceutical Import

The pharmaceutical trade corridor between the United Arab Emirates (UAE) and India has experienced notable growth from 2022 to 2026. In 2022, the total import value was $1.3 million USD, with 162 shipments from 17 UAE suppliers to 23 Indian buyers. By 2026, this value increased to $5.53 million USD, indicating a significant expansion in trade volume. This growth reflects the strengthening of bilateral trade relations and the UAE's growing role as a key supplier of pharmaceutical products to India.

The UAE's contribution to India's pharmaceutical imports remains modest but is on an upward trajectory. In 2024, the UAE exported pharmaceutical products worth $5.53 million USD to India, accounting for a small fraction of India's total pharmaceutical imports. India imports a diverse range of pharmaceutical products from the UAE, including finished formulations such as tablets, capsules, syrups, and injections. This diversity indicates the UAE's capability to supply a broad spectrum of pharmaceutical products to meet India's market demands.

Between 2024 and 2026, there have been significant developments in the pharmaceutical trade between the UAE and India. The Central Drugs Standard Control Organisation (CDSCO) has streamlined the registration process for foreign pharmaceutical products, facilitating easier market entry for UAE suppliers. Additionally, trade agreements between the two nations have been enhanced, leading to preferential duty rates and improved market access. These developments have contributed to the growth in pharmaceutical imports from the UAE to India.

IMPORT_REGULATORY

UAE pharmaceutical companies seeking to export products to India must navigate the CDSCO registration process. This involves obtaining an Import License (Form 10) and a Registration Certificate for each product. The process includes submitting an application with detailed product information, manufacturing details, and quality control measures. Clinical trial data may be required, depending on the product's classification. The timeline for registration varies but typically ranges from several months to a year, depending on the complexity of the product and the completeness of the application.

India requires that pharmaceutical products imported from the UAE adhere to Good Manufacturing Practice (GMP) standards. Manufacturing sites must be WHO-GMP certified, ensuring compliance with international quality standards. The CDSCO conducts inspections to verify adherence to these standards, assessing facilities, processes, and quality control measures. This rigorous evaluation ensures that imported pharmaceutical products are safe and effective for the Indian market.

To import pharmaceutical products into India, UAE companies must provide several key documents:

• Import License (Form 10): Authorizes the importation of pharmaceutical products into India.

• Registration Certificate: Confirms that the product is approved for sale in India.

• No Objection Certificate (NOC): Issued by the UAE regulatory authority, indicating no objection to the export of the product.

• Test License: Permits the testing of imported pharmaceutical products in India.

• Customs Documentation: Includes invoices, packing lists, and shipping documents required for customs clearance.

These documents ensure compliance with Indian regulations and facilitate the smooth importation of pharmaceutical products.

IMPORT_TRENDS

India's pharmaceutical imports from the UAE are dominated by specific therapeutic areas and product types. Notably, the top imported products include Semaglutide, Ibrutinib, and Pantoprazole, which are used in the treatment of diabetes, cancer, and gastrointestinal disorders, respectively. This indicates a significant demand for specialized and high-value pharmaceutical products from the UAE, reflecting India's focus on advanced therapies to address complex health conditions.

The UAE exports several innovative and specialty pharmaceutical products to India that are not manufactured domestically. These include novel biologics and targeted therapies such as Osimertinib and Carfilzomib, which are used in the treatment of specific types of cancer. The importation of these advanced therapies underscores India's reliance on international suppliers for cutting-edge treatments that are essential for managing complex diseases.

India's importation of pharmaceutical products from the UAE is driven by several factors:

• Patent Protection: The UAE offers patented drugs that are not yet available in India, fulfilling unmet medical needs.

• Technology Gaps: The UAE's advanced manufacturing capabilities provide products with superior quality and efficacy.

• Quality Requirements: The UAE's adherence to international quality standards ensures that imported products meet India's stringent regulatory requirements.

• Disease Burden: The prevalence of certain diseases in India necessitates the importation of specialized treatments not produced domestically.

These factors collectively contribute to the sustained demand for pharmaceutical imports from the UAE.

IMPORT_POLICY

India's import tariff structure for pharmaceutical formulations includes the following components:

• Most Favored Nation (MFN) Tariff Rates: These are the standard import duty rates applied to pharmaceutical products from all WTO member countries, including the UAE.

• Basic Customs Duty (BCD): A percentage of the product's value, levied on imported goods.

• Integrated Goods and Services Tax (IGST): Applied to the total value of the imported goods, including BCD.

• Health Cess: An additional levy imposed on certain pharmaceutical products to fund health initiatives.

These tariffs are subject to change based on government policies and trade agreements.

India and the UAE have engaged in bilateral trade agreements aimed at enhancing economic cooperation. While there is no comprehensive Free Trade Agreement (FTA) between the two countries, preferential duty rates have been established for certain products, including pharmaceuticals. These agreements facilitate smoother trade flows and provide mutual benefits, encouraging increased pharmaceutical imports from the UAE to India.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, allows for the granting of compulsory licenses under specific conditions, such as public health needs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported pharmaceuticals, to ensure affordability. These policies aim to balance the interests of patent holders and the accessibility of medicines to the Indian population.

IMPORT_LOGISTICS

Pharmaceutical products from the UAE to India are primarily transported via sea and air routes. Major sea routes include shipments from the Port of Jebel Ali in Dubai to Indian ports such as Mumbai and Chennai. Air shipments typically arrive at international airports like Indira Gandhi International Airport in Delhi and Chhatrapati Shivaji Maharaj International Airport in Mumbai. Transit times vary, with sea shipments taking approximately 7-10 days and air shipments around 3-5 days, depending on the specific ports and logistics arrangements.

The Port of Jebel Ali in Dubai is a key export hub for the UAE's pharmaceutical products, offering advanced facilities and connectivity. In India, major import ports handling pharmaceutical shipments include Jawaharlal Nehru Port Trust (JNPT) in Mumbai and Chennai Port. These ports are equipped with specialized facilities for handling pharmaceutical goods, ensuring efficient processing and distribution within India.

Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation and compliance with CDSCO regulations. Imported pharmaceutical products are subject to testing by the CDSCO to ensure they meet Indian quality standards. Maintaining the cold chain is critical for temperature-sensitive products; therefore, logistics providers must adhere to Good Distribution Practice (GDP) guidelines to ensure product integrity throughout the transit process.

IMPORT_OPPORTUNITY

Despite being a major pharmaceutical manufacturer, India imports specific products from the UAE due to factors such as patent protection, technology gaps, and the need for specialized treatments not produced domestically. The UAE's advanced manufacturing capabilities and adherence to international quality standards make it a valuable source for these specialized pharmaceutical products.

Several UAE-based pharmaceutical companies have established a presence in India, either through direct exports or by forming partnerships with Indian firms. These collaborations aim to leverage local manufacturing capabilities, enhance distribution networks, and navigate regulatory requirements effectively. Such strategies enable UAE companies to expand their market reach and cater to the diverse needs of the Indian pharmaceutical market.

India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme are designed to boost domestic pharmaceutical manufacturing. While these